The present invention relates to an injectable composition for bone regeneration, comprising 1 cc of 6% (w/v) hydrated collagen, 5000 units of thrombin, 0.5 ml of a mixed solution of lidocaine and epinephrine in which the epinephrine amount is 1:100,000 (v/v) on the basis of lidocaine, and acting by being injected into bone marrow. The composition according to the present invention activates undifferentiated cells in bone marrow and also activates the bone regeneration ability in bone marrow through the activation and differentiation of osteoclasts and osteoblasts, and can be a successful treatment method for medication-related osteonecrosis of the jaws (MRONJ) through a myeloid activation treatment method, uses various growth factors for myeloid activation and myeloid activation factors such as cytokines so as to allow for the development of treatment for the fundamental cause of MRONJ through a myeloid activation treatment method, and enables the complete regeneration of jaw bone conditions with respect to aesthetic and function, and thus can be effectively used in the treatment of various diseases caused by bone remodeling failure.

The kit for locating a vein is configured for use in inserting an intravenous (IV) catheter into a targeted vein of a patient. The kit for locating a vein is a transparent structure. The kit for locating a vein: a) removably attaches to the skin of the patient; b) numbs the skin of the patient; c) generates a vasomotor response; d) provides the ability to insert the IV catheter into the targeted vein while the kit for locating a vein remains attached to the patient; and, e) forms a dressing that captures bodily fluids. The kit for locating a vein comprises a parchment sheeting, a working media, a transparent pocket, and a plurality of apertures. The parchment sheeting, the working media, and the transparent pocket form a transparent composite textile structure. The plurality of apertures are apertures that are formed through the composite textile structure.

A wound healing composition is provided that includes a tissue adhesive or epithelial tissue healing agent and metal-modified cerium oxide nanoparticles (mCNPs). The nCNPs have a predominant 3+ surface charge and are in a range of about 3-35 nanometers (nm) in size and mixed in an amount that is in a range of about 0.01 to 0.1 weight percentage of a mixture having the tissue adhesive or epithelial tissue healing agent and the mCNPs. The metal (m) is a stable metallic metal with antimicrobial properties and non-ionizing. The mCNPs includes AgCNP2. A method is provided that uses the healing composition to treat a wound or epithelial tissue. The composition can be used to treat the skin or eye and/or subcutaneous tissue.

The present invention provides topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration of pain relief, and thereby provide more effective treatment to chronic open wounds, particularly those in non-mucosal tissue.

The present invention relates to a modified collagen obtainable by providing isolated collagen; freezing the isolated collagen; dehydrating the frozen collagen; and maturing the dehydrated collagen. Also disclosed are methods of preparing the modified collagen and uses thereof.

Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.

The invention relates to a method for the controlled delivery of a drug as a function of bioavailable drug concentration, a sensor device for detecting bioavailable drug concentration, and a delivery device that controls delivery of the drug based on the real-time detection of bioavailable drug concentration.

Film-forming gel compositions, useful in creating conformable and flexible gel bandages, can be formulate from a film-forming polymer, an amine-rich adhesion promoter, and a volatile solvent. The gel compositions form relatively thick films when dried on tissue, and can exhibit enhanced breathability to promote wound healing. In some cases, the film-forming gel composition can include lidocaine.

An on-demand drug release system provides an implantable drug delivery platform including a drug embedded in a controllable drug release structure. The drug release structure binds or compartmentalizes the drug until release of the drug is initiated by absorption of a near infrared release signal provided by a health care professional. The system allows more effective therapeutic use of opioids and other drugs, and prevents their abuse.

Provided herein are therapeutic acrylate compounds useful as medical adhesives, comprising a therapeutic agent covalently linked to a methacrylate or cyanoacrylate moiety. Adhesive compositions and kits, such as liquid sutures and bone cement also are provided along with uses for the compositions.